Actively Recruiting
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Led by Proteocyte Diagnostics Inc. · Updated on 2024-11-07
500
Participants Needed
3
Research Sites
616 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
CONDITIONS
Official Title
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia or oral squamous cell carcinoma
You will not qualify if you...
- Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Kingsway Oral & Maxillofacial Surgery
Edmonton, Alberta, Canada, T5M 3Z7
Actively Recruiting
2
University of Alberta
Edmonton, Alberta, Canada, T6G 1C9
Actively Recruiting
3
Western University
London, Ontario, Canada, N6A 5C1
Actively Recruiting
Research Team
J
Jason Hwang, PhD
CONTACT
M
Mark Darling, MSc, MChD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here